SCR7吡嗪
| 中文名称 | SCR7吡嗪 |
|---|---|
| 中文同义词 | 2,3-二氢-6,7-二苯基-2-硫代-4(1H)-蝶啶酮;SCR7吡嗪;SCR7 PYRAZINE产;6,7-二苯基-2-磺酰基-1H-蝶啶-4-酮;6,7-二苯基-2-硫氧基-2,3-二氢蝶呤-4(1H)-酮;SCR7 PYRAZINE,NHEJ抑制剂;SCR7 吡嗪,10 MM DMSO 溶液;SCR7 ,S7742 |
| 英文名称 | "6,7-diphenyl-2-sulfanylidene-1H-pteridin-4-one |
| 英文同义词 | "6,7-diphenyl-2-sulfanylidene-1H-pteridin-4-one;6,7-Diphenyl-2-thiolumazine;SCR7 pyrazine;6,7-Diphenyl-2-sulfanylpteridin-4-ol;2,3-Dihydro-6,7-diphenyl-2-thioxo-4(1H)-pteridinone;SCR7; SCR-7; SCR 7.;6,7-diphenyL;4(1H)-Pteridinone, 2,3-dihydro-6,7-diphenyl-2-thioxo- |
| CAS号 | 14892-97-8 |
| 分子式 | C18H12N4OS |
| 分子量 | 332.38 |
| EINECS号 | |
| 相关类别 | 标准品 |
| Mol文件 | 14892-97-8.mol |
| 结构式 |  |
SCR7吡嗪 性质
| 熔点 | 209 °C |
|---|---|
| 密度 | 1.42±0.1 g/cm3(Predicted) |
| 储存条件 | room temp |
| 溶解度 | 可溶于DMSO（少许）、甲醇（少许） |
| 形态 | 粉末 |
| 酸度系数(pKa) | 4.14±0.60(Predicted) |
| 颜色 | 淡黄色至深黄色 |
| InChI | 1S/C18H12N4OS/c23-17-15-16(21-18(24)22-17)20-14(12-9-5-2-6-10-12)13(19-15)11-7-3-1-4-8-11/h1-10H,(H2,20,21,22,23,24) |
| InChIKey | GSRTWXVBHGOUBU-UHFFFAOYSA-N |
| SMILES | O=C(C1=C(N2)N=C(C3=CC=CC=C3)C(C4=CC=CC=C4)=N1)NC2=S |
| CAS 数据库 | 14892-97-8 |
DNA Ligase IV
CRISPR/Cas9
SCR7 pyrazine (20-100 μM; 24 hours; MCF7 cells) treatment interferes with NHEJ in cells, leading to accumulation of unrepaired double-strand breaks (DSBs).
SCR7 pyrazine treatment shows a dose-dependent decrease in cell proliferation with IC
50
values of 40 μM, 34 μM, 44 μM, 8.5 μM, 120 μM, 10 μM and 50 μM for MCF7, A549, HeLa, T47D, A2780, HT1080 and Nalm6 cells, respectively.
In MCF7 cells, SCR7 pyrazine (20, 40 μM) treatment increases phosphorylation of ATM and activates p53, decreases MDM2, BCL2, resulting in activation of proapoptotic proteins, PUMA and BAX. And the shorter fragments of MCL1, PARP1, Caspase 3, and Caspase 9 cleavage are upregulated in a dose-dependent manner.
Western Blot Analysis
| Cell Line: | MCF7 cells |
| Concentration: | 20 μM, 40 μM, 100 μM |
| Incubation Time: | 24 hours |
| Result: | Showed an increase in levels of gH2AX foci and protein. |
SCR7 pyrazine (10 mg/kg; intraperitoneal injection; six doses; BALB/c mice) treatment significantly reduces breast adenocarcinoma-induced tumor and increases lifespan.
| Animal Model: | BALB/c mice injected with breast adenocarcinoma cells |
| Dosage: | 10 mg/kg |
| Administration: | Intraperitoneal injection; on alternate days (0, 2, 4, 6, 8, and 10) |
| Result: | Significantly reduced breast adenocarcinoma-induced tumor and increased lifespan. |
100-52-7
1004-76-8
14892-97-8
方法A: 将苯甲醛(466 mg, 4.4 mmol)溶于DMF(1.5 mL)和乙酸(0.5 mL)中，所得溶液缓慢加入至固体4,5-二氨基-6-羟基-2-巯基嘧啶(316 mg, 2.0 mmol)中。反应混合物于回流条件下加热3小时，随后冷却至室温，并缓慢加入10 mL冰水。析出的黄色固体经真空过滤收集，自然干燥。将干燥后的固体溶于60 mL氯仿中，过滤氯仿溶液以去除不溶物。将全部氯仿溶液上样至预先以二氯甲烷填充的硅胶柱上，以二氯甲烷:乙酸乙酯(2:1, v/v)为洗脱剂进行柱层析，收集第一个黄色条带。减压浓缩洗脱液，得到目标产物257 mg(0.77 mmol, 收率39%)。产物表征数据如下: 1H NMR (DMSO-d6) δ 13.42 (br.s, 1H), 12.82 (br.s, 1H), 7.43-7.34 (m, 10H); 13C NMR (DMSO-d6) δ 175.7, 158.5, 155.9, 149.1, 147.0, 137.7, 137.1, 129.8 (CH), 129.7 (CH), 129.5 (CH), 128.8 (CH), 128.3 (CH), 128.2 (CH), 127.2; HRMS (ESI) m/z calcd for C18H13N4OS [M+H]+ 333.0810, found 333.0802; IR (Nujol) νmax 3407 (br), 1698, 1633, 1552, 1126, 722, 695, 665 cm-1; mp 200-203 °C (dec.); UV/Vis λmax 380 nm (ε = 12,000 M-1 cm-1).
参考文献：
[1] Tetrahedron Letters, 2016, vol. 57, # 29, p. 3204 - 3207
安全信息
| WGK Germany | WGK 3 |
|---|---|
| 海关编码 | 2933.59.8000 |
| 存储类别 | 11 - 可燃固体 |
| 危险性类别 | 急性毒性 类别4 经口 |
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2025/12/22 | HY-107845 | SCR7吡嗪 SCR7 pyrazine | 14892-97-8 | 1 mg | 386元 |
| 2025/12/22 | HY-107845 | SCR7吡嗪 SCR7 pyrazine | 14892-97-8 | 10mM * 1mLin DMSO | 622元 |